VANCOUVER, B.C., CANADA (December 22nd, 2016) - M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”), is providing an update regarding its business strategy as it relates to the Company’s focus on weight management and women’s health treatments.
M Pharmaceutical Inc. is committed to developing and commercializing its innovative drug treatments and biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness. To complement its current product mix, M Pharma is exploring opportunities to include innovative technologies for weight management & women’s health applications.
“Our recent acquisitions, including C-103 and ToConceive, have provided M Pharma with a strong product mix with great potential for both our clients and shareholders. To complement the existing treatments, M Pharma is seeking additional innovative technologies which provide end users with realistic and effective solutions for weight management and better outcomes in the women’s health space,” noted Gary Thompson, President and CEO of M Pharmaceutical USA Inc. “Our team is actively working on the expansion of our treatment portfolio and we will continue to update our shareholders as we advance this initiative,” added Mr. Thompson.
The following points summarize the company’s product pipeline:
- M Pharma is developing patented, orally administered products for weight loss: C-103. A novel formulation of orlistat, C-103 has the potential to help patients lose significant weight with an acceptable side effect profile as compared to currently marketed products.
- ToConceiveis an easy to use natural conception lubricant that balances the pH of the vagina to support sperm survival. It also transforms the sperm to give the sperm the ability, or capacity, to fertilize the ovum for conception, a process called sperm capacitation.
- Potential innovative technologies for weight management purposes.
About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field.
M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the company’s biomedical & drug technologies, and the acquisition of the rights to a new product. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.